Axial

"Successful biotech companies are created from a special alchemy of science, business, technology, talent, and capital”

- Carl Hansen, Founder and CEO of AbCellera

Let the Best Drug Win with Errik Anderson axial.substack.com/p/let-the-be...

Errik Anderson is the CEO and Founder of ⁠⁠Alloy Therapeutics⁠⁠. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story

Expanding RNA's purview to more diseases. With the key caveat of excluding siRNA.

And offer almost a one-stop shop

From a technical perspective, Orbital is bringing technologies together to improve the durability of therapeutic RNA candidates and apply them to a broader range of cell types and tissues

Orbital Therapeutics develops RNA medicines. Founded in 2022 spinning out of Beam Therapeutics, the focus is on vaccines, immunomodulation, and protein replacement therapies. The business model is premised on collecting IP spanning different RNA modalities and delivery methods

Illumina sales Illumina sales
in year one: today:
$474,000 $474,000 per hour

The long-term idea is to use patient data generated to support discovery and development of new therapies. Bring various parts together where Scipher partners with payers, providers, and pharma companies to bring precision medicine products to patients.

They received Medicare coverage in 2023 for their PrismRA test which guides treatment selection for rheumatoid arthritis patients.

Studies show when PrismRA guides therapy, patients are 3 times more likely to reach remission

Scipher Medicine is a precision immunology company that matches patients with the most effective therapy for them. Developing PrismRA, a blood test that analyzes a patient's molecular signature to identify who is unlikely to respond to TNFi therapy so they can be prescribed an alternative

To solve treatment resistance in cell-cycle driven cancers and expand the therapeutic window for patients

Focusing on two candidates to bring into the clinic: IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor

Founded in 2019, the company is now building a pipeline of first-in-class and best-in-class programs. Key programs include HER2, CDK2/4 inhibitors along with newer targets.

Using its platform, built on 4 technologies, to explore chemical space to hone in on mechanisms of action and generate diverse, high-quality leads.

Iambic Therapeutics, previously known as Entos is a drug discovery company that uses physics-based AI algorithms and high-throughput experimentation to optimize drug candidates and profiles

Pfizer made an upfront cash payment of $25M to Dren Bio, with the company eligible to potentially receive more than $1B. To advance select oncology programs

The second program uses a proprietary bispecific antibody platform to engage myeloid and cancer cells, reprogram the tumor environment, stimulate phagocytosis, and activate T cells for sustained anti-tumor immunity. Partnering with Pfizer in 2022 using technology behind Dren's second drug candidate

The MoA is done through depletion of target cells via ADCC by means of fratricide, a method in which the same cell type induces ADCC on each other. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients

DR-01, the lead candidate, which induces antibody-mediated killing of cytotoxic immune cells involved in blood cancers. With potential use in autoimmune diseases too. The lead targets CD94 which is known to be up-regulated on large granular lymphocytic leukemia (LGLL) cells

Dren Bio develops antibody therapies for cancer and autoimmunity. Focusing on biologics designed to selectively target and eliminate pathogenic cells and agents. Founded in 2019, their pipeline is made up of two drug discovery programs

Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity www.nature.com/articles/s41...

Scientist Stories: Terry Orr-Weaver, Cell Division and Chromosome Segregation youtu.be/4OHiHK4GlSE

Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice www.pnas.org/doi/abs/10.1...

Scientist Stories: Sonja Schrepfer, The Future of Stem Cells and Hypoimmune Cell Therapies youtu.be/6sthpRhMZhg

Scientist Stories: Akiko Iwasaki, Immunology and Antibodies youtu.be/1gFzmoCr3Vk

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins www.nature.com/articles/s41...

Scientist Stories: Matthias Mann, Single Cell Proteomics and Precision Medicine youtu.be/yygFYaCpQA4

Deep Visual Proteomics defines single-cell identity and heterogeneity www.nature.com/articles/s41...

Geometric deep learning of RNA structure www.science.org/doi/10.1126/...

Founder Stories: Tassos Gianakakos, CEO of MyoKardia youtu.be/Haa6ORz__ig

Scientist Stories: Siddhartha Mukherjee, New Horizons in Cell Therapy for Cancer youtu.be/tDI3wl1KSxc